Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7363507 | 0.90 | MAPT (0.46) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL9693922 | 0.84 | CHRM1 (0.41) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL9693598 | 0.83 | TMEM97 (0.47) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL9693096 | 0.80 | MAPT (0.46) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL10272393 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL7328252 | 0.78 | KDM4E (0.43) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL12702905 | 0.77 | KDM4E (0.42) | LMNAKDM4EMAPTL3MBTL1RAB9A | |
| SCHEMBL7996906 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL10272389 | 0.74 | GRM5 (0.45) | SMN1; SMN2LMNAPABPC1ATMRXFP1 | |
| SCHEMBL9693522 | 0.73 | MAPT (0.41) | LMNAKDM4EMAPTTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-0168350-B1 | Certain ring-fused pyrazolo [3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY AG (CH) | 1992-05-06 | — | — | EP | disclosed |
| US-4814450-A | CENTRAL NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1989-03-21 | — | — | US | disclosed |
| US-4740512-A | Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
| US-4647566-A | Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating anxiety | CIBA-GEIGY CORPORATION (US) | 1987-03-03 | — | — | US | disclosed |
| US-4602014-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1986-07-22 | — | — | US | disclosed |
| EP-0168350-A2 | Certain ring-fused pyrazolo [3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | SMN1; SMN2 1943/4885LMNA 2214/4885PABPC1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.